STOCK TITAN

Theriva Biologics (TOVX) SEC Filings, Jun-Sep 2025

TOVX NYSE

Theriva Biologics, Inc. filings document a Nevada clinical-stage biotechnology issuer with common stock listed on the NYSE American under TOVX. The company’s Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical and regulatory updates for VCN-01, and material-event disclosures tied to its oncology development programs.

Theriva Biologics proxy statements cover stockholder meeting mechanics, governance matters and shareholder approval proposals related to warrant exercises and potential common-stock issuance under NYSE American rules. Other 8-K disclosures record material definitive agreements, including the SYN-020 license arrangement, alongside capital-structure, voting and corporate-update information relevant to the company’s development-stage business.

Rhea-AI Summary

Theriva Biologics, Inc. reported results of its 2025 annual stockholder meeting held on August 29, 2025. Stockholders approved Amendment No. 3 to the 2020 Stock Incentive Plan, increasing the number of shares of common stock the company may grant under the plan from 2,500,000 to 4,500,000, expanding the pool available for equity-based compensation.

Four directors – Jeffrey J. Kraws, Steven A. Shallcross, John Monahan and Jeffrey Wolf – were re-elected to serve until the next annual meeting. Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2025, approved on an advisory basis the compensation of named executive officers, and supported holding future advisory votes on executive pay every three years. The board determined to follow the three-year frequency in line with this vote.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
current report
-
Rhea-AI Summary

Theriva Biologics, Inc. filed a Form 10-Q reporting total assets of $35.83 million and cash and cash equivalents of $12.12 million as of June 30, 2025. The company recorded a quarterly net loss of $13.06 million and a six-month net loss of $17.38 million, driven by a sharp increase in general and administrative expenses and continued R&D spending. In the period the company met primary survival and safety endpoints in its VIRAGE Phase 2b trial for lead candidate VCN-01, which triggered a contractual milestone obligation and contributed to an increase in contingent consideration to $10.16 million. The acquired in-process R&D (IPR&D) asset is carried at $19.62 million and was tested for impairment with no charge recorded. The company raised gross proceeds of approximately $7.5 million in a May 2025 offering and had cash of about $9.5 million in early August 2025, with management stating that current cash is expected to be sufficient into the first quarter of 2026. The 10-Q discloses substantial doubt about the Company’s ability to continue as a going concern and the need to obtain additional financing or strategic transactions to fund planned clinical activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.02%
Tags
quarterly report
-
Rhea-AI Summary

Theriva Biologics, Inc. furnished a press release containing financial information for the quarter ended June 30, 2025, and attached that press release to this Current Report as Exhibit 99.1. The report also identifies an interactive data file as Exhibit 104.

The company states that the information in Item 2.02 and the attached press release is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. The Form 8-K is signed by Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer. No financial figures are included in the Form text provided here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.02%
Tags
current report
Schedule 13G
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
other
-
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
annual report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
proxy
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
current report
-
Rhea-AI Summary

Theriva Biologics (NYSE: TOVX) has announced a significant at-the-market (ATM) offering through an amended sales agreement with A.G.P./Alliance Global Partners. The company plans to offer up to $2.53 million worth of common stock through this facility.

Key details of the ATM offering include:

  • Sales will be conducted through A.G.P./Alliance Global Partners as Sales Agent
  • Sales Agent commission rate set at 3.0% of gross sales price per share
  • Offering falls under the previously effective S-3 Registration Statement (File No. 333-279077) from September 2024
  • Sales will be made through methods qualifying as "at the market offering" under Rule 415(a)(4)

The filing includes legal validation through Parsons Behle & Latimer's opinion on share validity. This offering provides Theriva with flexibility to raise capital as needed, though there's no obligation to sell any specific amount of shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
current report
-
Rhea-AI Summary

Theriva Biologics (TOVX) has filed a prospectus supplement for an at-market offering of up to $2,534,352 worth of common stock through A.G.P./Alliance Global Partners. The offering is made under an Amended and Restated At Market Issuance Sales Agreement from February 2021, with subsequent amendments.

Key financial details:

  • Previous sales: ~569,000 shares generating net proceeds of ~$3.6M in 2024
  • Current stock price: $0.465 (as of June 17, 2025)
  • Public float value: ~$12.9M based on 9,049,241 non-affiliate shares
  • Sales agent commission: up to 3.0% of gross sales

The company, following its March 2022 acquisition of VCN Biosciences, focuses on developing cancer therapeutics. Their lead candidate, VCN-01, is an oncolytic adenovirus currently in Phase 2b trials for pancreatic cancer and Phase 1 studies for retinoblastoma and other solid tumors. The offering is limited by the one-third public float rule under Form S-3 requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
prospectus

FAQ

How many Theriva Biologics (TOVX) SEC filings are available on StockTitan?

StockTitan tracks 69 SEC filings for Theriva Biologics (TOVX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Theriva Biologics (TOVX)?

The most recent SEC filing for Theriva Biologics (TOVX) was filed on November 18, 2026.